Welcome to our dedicated page for C4 Therapeutics SEC filings (Ticker: CCCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
C4 Therapeutics’ 10-Ks read like molecular biology textbooks. Investors hunting for how degrader programs move from lab to clinic or when a strategic collaboration alters cash burn often wade through hundreds of pages. Add Form 4 disclosures about scientists exercising options, and the picture gets even more intricate.
Stock Titan turns those challenges into clarity. Our AI-powered summaries deliver “C4 Therapeutics SEC filings explained simply,” mapping each disclosure to what matters: pipeline milestones, royalty obligations, and trial funding. Whether you need the “C4 Therapeutics quarterly earnings report 10-Q filing” or an “8-K material events explained” after a pivotal data release, every document arrives in real time, complete with plain-English context.
- Form 4 alerts flag “C4 Therapeutics insider trading Form 4 transactions” and “C4 Therapeutics executive stock transactions Form 4” the moment they hit EDGAR.
- Annual report 10-K sections on TORPEDO® platform costs are “C4 Therapeutics annual report 10-K simplified” for quick ratio checks.
- Proxy statements reveal “C4 Therapeutics proxy statement executive compensation” details without paging through exhibits.
Use our interactive dashboards to compare R&D spend quarter over quarter, track “C4 Therapeutics earnings report filing analysis,” and monitor “C4 Therapeutics Form 4 insider transactions real-time” before making allocation decisions. From “understanding C4 Therapeutics SEC documents with AI” to drilling into segment footnotes, Stock Titan delivers the full stack of filings insight so you can focus on valuing first-in-class degraders, not decoding legal prose.
C4 Therapeutics (NASDAQ: CCCC) Q2 2025 10-Q highlights
- Revenue: $6.5 m from collaborations, down 46 % YoY (Q2 24: $12.0 m) as Biogen–related income rolled off.
- Expenses: R&D $26.2 m (+10 % YoY); G&A $8.8 m (-10 % YoY). Total op-ex $35.0 m (+4 %).
- Losses: Operating loss widened to $28.5 m; net loss $26.0 m (-$0.37 pps) versus $17.7 m (-$0.26 pps) a year ago. 1H 25 net loss $52.3 m.
- Cash runway: Cash, cash equivalents & marketable securities were $223 m at 6-30-25 (vs. $267 m at 12-31-24); management projects ≥12-month runway.
- Balance sheet: Deferred revenue $43.8 m, reflecting future work under Roche, MKDG, Merck and Betta deals; no debt.
- Collaboration momentum: Earned $1 m discovery milestone (MKDG) and two $2 m lead-series milestones (Roche). Q2 revenue mix: MKDG 53 %, Roche 30 %, Merck 16 %, Betta 1 %.
- Share count: 71.2 m outstanding (7-29-25) after equity comp and ESPP; authorized shares doubled to 300 m.
- Guidance & risk: Company remains clinical-stage with no product sales; relies on external funding and partner milestones; accumulated deficit $686 m.
The filing affirms strategic focus on protein-degrader oncology programs (e.g., CFT8919, DACs) while controlling G&A. Near-term catalysts hinge on progress within partnered pipelines and internal Phase 1 assets.
C4 Therapeutics Director Utpal Koppikar received a stock option grant on June 18, 2025, as reported in this Form 4 filing. The derivative securities transaction involved:
- Grant of 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting
The options are subject to continued service as a Board member through the vesting date. This grant appears to be part of the company's director compensation program. The transaction was reported by attorney-in-fact Jolie M. Siegel on June 20, 2025.
C4 Therapeutics Director Owen Hughes received a stock option grant on June 18, 2025, representing a significant insider transaction. The derivative securities transaction details include:
- Granted 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting schedule: Full vesting upon earlier of June 18, 2026 or next annual stockholder meeting
This Form 4 filing indicates standard board compensation practices through equity grants. The vesting conditions require continued service as a board member, aligning the director's interests with long-term shareholder value. The transaction was executed under direct ownership, with attorney Jolie M. Siegel signing as the authorized representative.
FAQ
What is the current stock price of C4 Therapeutics (CCCC)?
What is the market cap of C4 Therapeutics (CCCC)?
